

# NexoBrid®

(anacaulase-bcdb)

# NexoBrid® (anacaulase-bcdb) Product Ordering

NexoBrid® is a first-line enzymatic agent indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns.<sup>1,2</sup>

Please see full Indication, including Limitations of Use and IMPORTANT SAFETY INFORMATION below and Full Prescribing Information.

NexoBrid is available by prescription and should only be administered by a healthcare provider.



Product illustration

## Ordering Information<sup>1</sup>

<b>Product Name</b>	NexoBrid (anacaulase-bcdb)
<b>Indication</b>	NexoBrid is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
<b>Product Description</b>	The drug substance in NexoBrid (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants ( <i>Ananas comosus</i> ).
<b>Dosage Form &amp; Strength</b>	5 g lyophilized powder (containing 4.85 grams of anacaulase-bcdb) with a 50 g gel vehicle, for treatment of up to 450 cm <sup>2</sup> of burn area after mixing.
<b>How Supplied</b>	NexoBrid (anacaulase-bcdb) for topical gel, 8.8%, is supplied as a package containing two components, a sterile, preservative-free, off-white to light tan lyophilized powder in a glass vial and a sterile, preservative-free, clear and colorless gel vehicle in a glass jar, that are mixed prior to application.
<b>Product Packaging</b>	Carton Dimensions: 90 mm (height) x 112 mm (width) x 68 mm (length)
<b>Storage and Handling</b>	Store and transport NexoBrid package upright. Must be refrigerated at 2°C to 8°C (36 °F to 46 °F) in the original carton to protect from light. Do not freeze. Shelf life of 3 years.
<b>NDC Number</b>	NDC 69866-2005-3

## Specialty Distributor Item Numbers

Specialty Distributor	Item Number
AmerisourceBergen	10277892
Cardinal Health	5840814
McKesson	2694719
DMS Pharmaceutical	005418

## Ordering Information

Age	Dosage	Unit Orders
Adults	<ul style="list-style-type: none"> <li>Up to 15% BSA in one application</li> <li>A second application may be applied 24 hours later—total treatment area must not exceed 20% BSA</li> </ul>	6 units = ~15% BSA
Pediatric Patients 6-17 Years of Age	<ul style="list-style-type: none"> <li>Up to 15% BSA in one application</li> <li>A second application is not recommended</li> </ul>	6 units = ~15% BSA
Pediatric Patients <6 Years of Age	<ul style="list-style-type: none"> <li>Up to 10% BSA in one application</li> <li>A second application is not recommended</li> </ul>	4 units = ~10% BSA

## New Product Set Up

For new product set up, ensure product information is included in the designated hospital ordering system.

## Additional Ordering Information

For additional ordering inquiries or tracking information, please call 1-833-950-1663 or email [GMB-SPS-VERICEL@cordlogistics.com](mailto:GMB-SPS-VERICEL@cordlogistics.com).

## INDICATION

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

### Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for:

- Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
- Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

## WARNINGS AND PRECAUTIONS

### Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NEXOBRID (if applicable) and initiate appropriate therapy.

Healthcare personnel should take appropriate precautions to avoid exposure when preparing and handling NEXOBRID (e.g., gloves, surgical masks, other protective coverings, as needed).

### Coagulopathy

Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.

### ADVERSE REACTIONS

The most common adverse reactions (>5%) in adults were pruritus, pyrexia, wound complication, anemia, vomiting and insomnia. The most common adverse reactions (>5%) in pediatric patients were pruritus, pyrexia and vomiting.

### USE IN SPECIAL POPULATIONS

#### Geriatric Use

Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see Full Prescribing Information.



References 1. NEXOBRID Prescribing Information. Cambridge, MA. Vericel Corporation; 2023.

2. Muhammad ZA, Ahmad T. Therapeutic uses of pineapple-extracted bromelain in surgical care. J Pak Med Assoc. 2017;67(1):121-125.

Vericel® and the Vericel logo are registered trademarks of Vericel Corporation.

NexoBrid® is a registered trademark of MediWound Ltd.

©2024 Vericel Corporation. All rights reserved. PP.US.NXB.0096 v4.0